Basic Information
| RNALocate ID: | RLID:11001827 |
| RNA Symbol: | hsa-miR-152-3p |
| Localization: | Extracellular vesicle |
RNA Information
| RNA Name: | hsa-miR-152 |
| RNA ID: | miRBase:MIMAT0000438 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 22849433 |
| Tissue/Cell Line: | HEK-293T cells |
| Method: | Next-generation RNA sequencing |
| Description: | The total numbers of reads >15 bp matching each miRNA were calculated. These values were then normalized to number of reads per million mapped (RPMM) in each library, to enable direct comparison of expression levels. As a measure of the relative levels of expression of individual miRNAs in cells and EVs, the log (base two) of the ratio of the read number in EVs over that in cells was calculated (log2 (EV/cell)). The miRNA expression data for cells and EVs is presented in Additional file 1: Table S1. Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001792 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01001793 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001794 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001795 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001796 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11001822 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11001823 | Exosome | Ovarian follicular fluid | 22116803 |
| RLID:11001824 | Exosome | Breast milk | 22211110 |
| RLID:11001825 | Exosome | Brain tissue | 23382797 |
| RLID:11001826 | Exosome | Plasma | 23663360 |
| RLID:11001828 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000087 | Exosome | Breast milk|Tongue tissue | |
| RLID-D:11000366 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-152-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-17001 |
| MNDR | hsa-miR-152-3p | Oral squamous cell carcinoma | MNDR-E-MI-17002 |
| MNDR | hsa-miR-152-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-17003 |
| MNDR | hsa-miR-152-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-17004 |
| MNDR | hsa-miR-152-3p | Lymphoma | MNDR-E-MI-17005 |
| MNDR | hsa-miR-152-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-17006 |
| MNDR | hsa-miR-152-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-17007 |
| MNDR | hsa-miR-152-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-17008 |
| MNDR | hsa-miR-152-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-17009 |
| MNDR | hsa-miR-152-3p | Her2-receptor positive breast cancer | MNDR-E-MI-17010 |
| MNDR | hsa-miR-152-3p | Niemann-pick disease type c | MNDR-E-MI-17011 |
| MNDR | hsa-miR-152-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-17012 |
| MNDR | hsa-miR-152-3p | Prostate cancer | MNDR-E-MI-17013 |
| MNDR | hsa-miR-152-3p | Gastric cancer | MNDR-E-MI-17014 |
| MNDR | hsa-miR-152-3p | Alzheimer disease | MNDR-E-MI-17015 |
| MNDR | hsa-miR-152-3p | Bladder cancer | MNDR-E-MI-17016 |
| MNDR | hsa-miR-152-3p | Dysautonomia familial | MNDR-E-MI-17017 |
| MNDR | hsa-miR-152-3p | Head and neck cancer | MNDR-E-MI-17018 |
| MNDR | hsa-miR-152-3p | Dengue disease | MNDR-E-MI-17019 |
| MNDR | hsa-miR-152-3p | Cardiovascular disease | MNDR-E-MI-17020 |
| MNDR | hsa-miR-152-3p | Carotid stenosis | MNDR-E-MI-17021 |
| MNDR | hsa-miR-152-3p | Brain cancer | MNDR-E-MI-17022 |
| MNDR | hsa-miR-152-3p | Lung cancer | MNDR-E-MI-17023 |
| MNDR | hsa-miR-152-3p | Endometrial cancer | MNDR-E-MI-17024 |
| MNDR | hsa-miR-152-3p | Parkinson disease | MNDR-E-MI-17025 |
| MNDR | hsa-miR-152-3p | Niemann-pick disease | MNDR-E-MI-17026 |
| MNDR | hsa-miR-152-3p | Breast cancer | MNDR-E-MI-17027 |
| MNDR | hsa-miR-152-3p | Thyroid cancer | MNDR-E-MI-17028 |
| MNDR | hsa-miR-152-3p | Pancreatic cancer | MNDR-E-MI-17029 |
| MNDR | hsa-miR-152-3p | Malignant melanoma | MNDR-E-MI-17030 |
| MNDR | hsa-miR-152-3p | Gaucher disease | MNDR-E-MI-17031 |
| MNDR | hsa-miR-152-3p | Rectum adenocarcinoma | MNDR-E-MI-17032 |
| MNDR | hsa-miR-152-3p | Nephroblastoma | MNDR-E-MI-17033 |
| MNDR | hsa-miR-152-3p | Colon cancer | MNDR-E-MI-17034 |
| MNDR | hsa-miR-152-3p | Colon adenocarcinoma | MNDR-E-MI-17035 |
| MNDR | hsa-miR-152-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-17036 |
| MNDR | hsa-miR-152-3p | Familial ovarian cancer | MNDR-E-MI-17037 |
| MNDR | hsa-miR-152-3p | Prostate adenocarcinoma | MNDR-E-MI-17038 |
| MNDR | hsa-miR-152-3p | Hematologic cancer | MNDR-E-MI-17039 |
| MNDR | hsa-miR-152-3p | Carcinoma ductal breast | MNDR-E-MI-17040 |
| MNDR | hsa-miR-152-3p | Glioblastoma | MNDR-E-MI-17041 |
| MNDR | hsa-miR-152-3p | Glioma | MNDR-E-MI-17042 |
| MNDR | hsa-miR-152-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-17043 |
| MNDR | hsa-miR-152-3p | Meningioma | MNDR-E-MI-17044 |
| MNDR | hsa-miR-152-3p | Liver neoplasms | MNDR-E-MI-17045 |
| MNDR | hsa-miR-152-3p | Cervical adenocarcinoma | MNDR-E-MI-17046 |
| MNDR | hsa-miR-152-3p | Gastric adenocarcinoma | MNDR-E-MI-17047 |
| MNDR | hsa-miR-152-3p | Lung carcinoma | MNDR-E-MI-17048 |
| MNDR | hsa-miR-152-3p | Lung squamous cell carcinoma | MNDR-E-MI-17049 |
| MNDR | hsa-miR-152-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-17050 |
| MNDR | hsa-miR-152-3p | Lung adenocarcinoma | MNDR-E-MI-17051 |
| MNDR | hsa-miR-152-3p | Thyroid carcinoma | MNDR-E-MI-17052 |
| MNDR | hsa-miR-152-3p | Ovarian carcinoma | MNDR-E-MI-17053 |
| MNDR | hsa-miR-152-3p | Bladder urothelial carcinoma | MNDR-E-MI-17054 |
| MNDR | hsa-miR-152-3p | Pancreatic adenocarcinoma | MNDR-E-MI-17055 |
| MNDR | hsa-miR-152-3p | Carcinoma renal cell | MNDR-E-MI-17056 |
| MNDR | hsa-miR-152-3p | Renal clear cell carcinoma | MNDR-E-MI-17057 |
| MNDR | hsa-miR-152-3p | Cholangiocarcinoma | MNDR-E-MI-17058 |
| MNDR | hsa-miR-152-3p | Esophageal cancer | MNDR-E-MI-17059 |
| MNDR | hsa-miR-152-3p | Liver cirrhosis | MNDR-E-MI-17060 |
| MNDR | hsa-miR-152-3p | Lung small cell carcinoma | MNDR-E-MI-17061 |
| MNDR | hsa-miR-152-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-17062 |
| MNDR | hsa-miR-152-3p | Breast invasive carcinoma | MNDR-E-MI-17063 |
| MNDR | hsa-miR-152-3p | Early hepatocellular carcinoma | MNDR-E-MI-17064 |
| MNDR | hsa-miR-152-3p | Familiar ovarian carcinoma | MNDR-E-MI-17065 |
| MNDR | hsa-miR-152-3p | B-cell lymphoma | MNDR-E-MI-17066 |
| MNDR | hsa-miR-152-3p | Rheumatoid arthritis | MNDR-E-MI-17067 |
| MNDR | hsa-miR-152-3p | Neuroblastoma | MNDR-E-MI-17068 |
| MNDR | hsa-miR-152-3p | Chronic fatigue syndrome | MNDR-E-MI-17069 |
| MNDR | hsa-miR-152-3p | Hodgkin lymphoma | MNDR-E-MI-17070 |
| MNDR | hsa-miR-152-3p | Neuromyelitis optica | MNDR-E-MI-17071 |
| MNDR | hsa-miR-152-3p | Acute myeloid leukemia | MNDR-E-MI-17072 |
| MNDR | hsa-miR-152-3p | Colorectal cancer | MNDR-E-MI-17073 |
| MNDR | hsa-miR-152-3p | Nasopharynx carcinoma | MNDR-E-MI-17074 |
| MNDR | hsa-miR-152-3p | Type 2 diabetes mellitus | MNDR-E-MI-17075 |
| MNDR | hsa-miR-152-3p | Acute lymphocytic leukemia | MNDR-E-MI-17076 |
| MNDR | hsa-miR-152-3p | Ovarian epithelial cancer | MNDR-E-MI-17077 |
| MNDR | hsa-miR-152-3p | Nasopharyngeal cancer | MNDR-E-MI-17078 |
| MNDR | hsa-miR-152-3p | Prostatic neoplasms | MNDR-E-MI-17079 |
| MNDR | hsa-miR-152-3p | Epstein-barr virus infections | MNDR-E-MI-17080 |
| MNDR | hsa-miR-152-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-17081 |
| MNDR | hsa-miR-152-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-17082 |
| MNDR | hsa-miR-152-3p | Stroke lacunar | MNDR-E-MI-17083 |
| MNDR | hsa-miR-152-3p | Breast cancer her3+ negative | MNDR-E-MI-17084 |
| MNDR | hsa-miR-152-3p | High grade dysplastic nodule | MNDR-E-MI-17085 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ADAM17 | Homo sapiens | RR00040511 |
TOP